Floatz logo

Milatuzumab

Leukemia, Prolymphocytic

Gilead Sciencesmonoclonal_antibodyPhase 1/2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Leukemia, Prolymphocytic cohort.

Asset / SponsorPhaseRating
Auranofin
University of Kansas Medical Center
Phase 2B
Veltuzumab
Gilead Sciences
Phase 1/2CCC

Same molecule, other indications

Milatuzumab is also rated in:

NHLDormant
B
Indicative ·
58 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
Lymphoma, Large-CellDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →